Neurodegenerative Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Taken together, these data expand our understanding of HDAC1-3 inhibitor binding kinetics, and further delineate the specific combinations of structural and kinetic features of HDAC inhibitors that are optimal for upregulating PGRN expression in human neurons and thus may have translational relevance in neurodegenerative disease.
|
31330099 |
2019 |
Thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
|
30669676 |
2019 |
Diabetic peripheral neuropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
STAT3 phosphorylation mediates high glucose-impaired cell autophagy in an HDAC1-dependent and -independent manner in Schwann cells of diabetic peripheral neuropathy.
|
30913399 |
2019 |
Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The present results suggest that the inhibition of HDAC1 suppresses the pathogenic processes that lead to the degeneration of motoneurons in mitochondrial diseases.
|
31614134 |
2019 |
Liver regeneration disorder
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We have recently shown in a zebrafish model of LPC-driven liver regeneration that inhibition of Hdac1 activity through MS-275 treatment enhances <i>sox9b</i> expression in LPCs and impairs LPC-to-hepatocyte differentiation.
|
30992706 |
2019 |
Thymic Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
|
31304633 |
2019 |
Cardiac fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that ellagic acid significantly reduced protein expression of HDAC1, mRNA expression of collagen I, collagen III, MMP-2 and MMP-9 and the area of cardiac fibrosis in MI rats.
|
31168029 |
2019 |
Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HDAC1 was expressed in reactive ducts and hepatocyte buds of liver tissues from patients with cirrhosis.
|
30267710 |
2019 |
Coronary Artery Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicated that RFX1 expression deficiency in CD14+ monocytes from CAD patients contributed to MCP1 overexpression <i>via</i> a deficiency of recruitments of HDAC1 and SUV39H1 in the <i>MCP1</i> promoter, which highlighted the vital role of RFX1 in the pathogenesis of CAD.
|
31737059 |
2019 |
Chronic kidney disease stage 5
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified 2 genes, histone deacetylase 1 (HDAC1) and HDAC2, contributing to the pathogenesis of proteinuric kidney diseases, the leading cause of end-stage kidney disease. mRNA expression profiling from proteinuric mouse glomeruli was linked to Connectivity Map databases, identifying HDAC1 and HDAC2 with the differentially expressed gene set reversible by HDAC inhibitors.
|
30776024 |
2019 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
RBBP4 binds to the HIV-1 long terminal repeat (LTR), represses HIV-1 LTR-mediated transcription through recruiting nuclear receptor subfamily 2 group F member 1(NR2F1) and histone deacetylase 1 and 2 (HDAC1/2) to HIV-1 LTR, and further controls local histone 3 (H3) deacetylation and chromatin compaction.
|
31435636 |
2019 |
Carcinoma, Basal Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
The GLI1 transcription factor must maintain maximal Hedgehog pathway output in basal cell carcinomas (BCCs), and we have previously shown that resistant BCCs increase GLI1 deacetylation through atypical protein kinase Cι/λ (aPKC) and HDAC1.
|
30503211 |
2019 |
Alcohol Use Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study demonstrated that a new compound designed to target HDAC-1 is effective in reducing ethanol intake and relapse in rats and further confirm the interest of pursuing research to study the exact mechanism by which such inhibitor may be useful to treat AUDs.
|
29713786 |
2018 |
Autoimmune Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Combined inhibition of HDAC1/2 and Brd4 resolved the aberrant ISG expression detected in cells derived from patients with two inherited interferonopathies, ISG15 and USP18 deficiencies, defining a novel therapeutic approach to ISG-associated autoimmune diseases.
|
30463877 |
2018 |
Blast Phase
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients in accelerated phase CML (CML-AP) and blast phase CML (CML-BP) showed lower expressions of MEG3 and miR-147 and higher expressions of DNMT1, DNMT3B, MBD2, MECP2 and HDAC1 compared to the controls.
|
30072211 |
2018 |
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Histone deacetylase 1 (HDAC1) plays important roles in self-renewal of stem cells as well as the recovery of brain disorders.
|
30662396 |
2018 |
Mucinous Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HDAC1 was detected in the nucleus of all cases with MUC, followed by CCC (80%), SEC (73%), and EMC (53%).
|
29456726 |
2018 |
Transient Ischemic Attack
|
0.010 |
Biomarker
|
disease |
BEFREE |
TOPK Promotes Microglia/Macrophage Polarization towards M2 Phenotype via Inhibition of HDAC1 and HDAC2 Activity after Transient Cerebral Ischemia.
|
29896413 |
2018 |
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
VPA could induce CHD (P < 0.001) and inhibit mRNA or protein expression of Hdac1/2/3 as well as Vangl2/Scrib in fetal hearts, in association with total Hdac activity repression (all P < 0.05).
|
30127218 |
2018 |
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate a novel pathophysiological role for HDAC1 in EAE and provide evidence that selective inhibition of HDAC1 might be a promising strategy for the treatment of MS.
|
28964722 |
2018 |
Leukemia, Myeloid, Accelerated Phase
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients in accelerated phase CML (CML-AP) and blast phase CML (CML-BP) showed lower expressions of MEG3 and miR-147 and higher expressions of DNMT1, DNMT3B, MBD2, MECP2 and HDAC1 compared to the controls.
|
30072211 |
2018 |
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate a novel pathophysiological role for HDAC1 in EAE and provide evidence that selective inhibition of HDAC1 might be a promising strategy for the treatment of MS.
|
28964722 |
2018 |
Status Epilepticus
|
0.010 |
Biomarker
|
disease |
BEFREE |
The coimmunoprecipitation assay revealed that the interaction between yin yang 1 and histone deacetylase 1 in the cortex and hippocampus was enhanced during SE, indicating that this interaction is also responsible for the CYP2D4 suppression.
|
29175413 |
2018 |
Cystadenocarcinoma, Serous
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HDAC1 nuclear expression adversely affected overall survival in SEC (P=0.02) and EMC (P=0.03), and HDAC7 cytoplasmic expression in CCC was associated with a poor prognosis (P=0.06).
|
29456726 |
2018 |
Renal dysgenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Finally, although HDAC1/2-deficient NPCs and RVs overexpress hyperacetylated p53, <i>Trp53</i> deletion failed to rescue the renal dysgenesis.
|
29712641 |
2018 |